Revance Therapeutics is a biotechnology company focused on innovative aesthetic and therapeutic offerings. They develop and commercialize products like DAXXIFY (daxibotulinumtoxinA-lanm) for glabellar lines and cervical dystonia, and the RHA Collection of dermal fillers. Their target audience includes healthcare professionals and patients seeking aesthetic treatments. The unique selling proposition is their commitment to elevating patient and physician experiences through cutting-edge science and a diverse product portfolio, setting a new standard in healthcare. Revance aims to transform patient experiences with innovative solutions.